ASSET PURCHASE AGREEMENTAsset Purchase Agreement • December 21st, 2017 • Quantrx Biomedical Corp • Surgical & medical instruments & apparatus • Delaware
This ASSET PURCHASE AGREEMENT (this “Agreement”), dated December 14, 2017, is made by and between QuantRx Biomedical Corporation, a Nevada corporation (“Seller”), and Preprogen LLC, a Delaware limited liability company (“Buyer”). Buyer and Seller are collectively referred to herein as the “Parties” and each individually as a “Party”.
INTELLECTUAL PROPERTY LICENSE AGREEMENTIntellectual Property License Agreement • December 21st, 2017 • Quantrx Biomedical Corp • Surgical & medical instruments & apparatus • Delaware
This Intellectual Property License Agreement (“Agreement”) is entered into as of December 14, 2017 (the “Effective Date”), by and between QuantRX Biomedical Corporation, a Nevada Corporation (“Licensee”), and Preprogen LLC, a Delaware corporation (“Licensor”).
PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • December 21st, 2017 • Quantrx Biomedical Corp • Surgical & medical instruments & apparatus • Delaware
This PATENT ASSIGNMENT AGREEMENT (“Agreement”) is made as of December 14, 2017, by and between QuantRx Biomedical Corporation, a Nevada corporation (“Assignor”), and Preprogen LLC, a Delaware limited liability company (“Assignee”).
ESCROW AGREEMENT (Basic Three Party Escrow)Escrow Agreement • December 21st, 2017 • Quantrx Biomedical Corp • Surgical & medical instruments & apparatus • New York
THIS ESCROW AGREEMENT is entered into as of December 14, 2017, by and among Preprogen LLC, a Delaware limited liability company (“Party A”), QuantRx Biomedical Corporation, a Nevada corporation (“Party B”, and together with Party A, sometimes referred to individually as “Party” and collectively as the “Parties”), and JPMorgan Chase Bank, N.A. (the “Escrow Agent”).
TRADEMARK ASSIGNMENT AGREEMENTTrademark Assignment Agreement • December 21st, 2017 • Quantrx Biomedical Corp • Surgical & medical instruments & apparatus • Delaware
This TRADEMARK ASSIGNMENT AGREEMENT (this “Trademark Assignment Agreement”) is made as of December 14, 2017 by and between QuantRx Biomedical Corporation, a Nevada corporation (“Assignor”), and Preprogen LLC, a Delaware limited liability company (“Assignee”).
